Advertisement
Screener

Twist Bioscience Corporation (TWST) EBITDA

Twist Bioscience Corporation (TWST) EBITDA

  • 2026-06-30: Basis Reported; EBITDA -$29.5M; Operating income (m); Depreciation and amortization (m).
  • 2026-03-31: Basis Reported; EBITDA -$39.45M; Operating income (m); Depreciation and amortization (m).
  • 2025-12-31: Basis Reported; EBITDA -$26.71M; Operating income (m); Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA -$23.93M; Operating income (m); Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history
2017-09-30 to 2025-12-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported-$29.5M(m)(m)$118.38M-24.92%$9.76M*$1.11M*(m)$18.02M$80.71M$311.00K
2026-03-31Reported-$39.45M(m)(m)$110.72M-35.63%$7.89M*-$17.56M*(m)$19.70M$76.08M$43.00K
2025-12-31Reported-$26.71M(m)(m)$103.7M-25.75%$9.97M-$24.81M(m)$17.13M$69.74M$253.00K
2025-09-30Reported-$23.93M(m)(m)$99.01M-24.17%(m)(m)(m)(m)(m)(m)
2025-06-30Reported-$24.06M(m)(m)$96.06M-25.04%$9.16M*-$1.40M*(m)$18.05M$63.37M$191.00K
2025-03-31Reported-$35.16M(m)(m)$92.79M-37.89%$4.14M*-$12.99M*(m)$23.92M$63.67M$175.00K
2024-12-31Reported-$28.26M(m)(m)$88.71M-31.86%$2.27M-$21.43M(m)$21.31M$56.18M$97.00K
2024-09-30Reported-$29.39M(m)(m)$84.71M-34.69%(m)(m)(m)(m)(m)(m)
2024-06-30Reported-$80.62M(m)(m)$81.46M-98.97%$965.00K*-$6.38M*(m)$22.47M$56.79M$191.00K
2024-03-31Reported-$40.59M(m)(m)$75.3M-53.90%$603.00K*-$19.42M*(m)$24.15M$55.62M$345.00K
2023-12-31Reported-$38.81M(m)(m)$71.5M-54.28%$1.51M-$22.97M(m)$23.10M$52.84M$120.00K
2023-09-30Reported-$41.61M(m)(m)$66.95M-62.16%(m)(m)(m)(m)(m)(m)
2023-06-30Reported-$52.29M(m)(m)$63.74M-82.04%$4.51M*-$23.41M*(m)$24.53M$46.06M$622.00K
2023-03-31Reported-$54.61M(m)(m)$60.18M-90.74%$9.05M*-$44.29M*(m)$27.38M$53.97M$676.00K
2022-12-31Reported-$39.34M(m)(m)$54.24M-72.52%$11.82M-$54.07M(m)$31.24M$42.32M$76.00K
2022-09-30Reported-$51.92M(m)(m)$57.31M-90.60%(m)(m)(m)(m)(m)(m)
2022-06-30Reported-$56.72M(m)(m)$56.11M-101.08%$40.64M*-$34.13M*(m)$36.84M$53.69M-$149.00K
2022-03-31Reported-$56.83M(m)(m)$48.13M-118.09%$31.97M*-$42.34M*(m)$31.23M$54.00M-$149.00K
2021-12-31Reported-$52.79M(m)(m)$42.02M-125.64%$12.78M-$46.65M(m)$22.63M$51.10M-$10.40M
2021-09-30Reported-$37.38M(m)(m)$37.95M-98.50%(m)(m)(m)(m)(m)(m)
2021-06-30Reported-$39.37M(m)(m)$35.02M-112.44%$6.94M*-$27.96M*(m)$19.84M$34.48M-$2.38M
2021-03-31Reported-$35.54M(m)(m)$31.2M-113.90%$8.40M*-$24.55M*(m)$15.79M$34.39M$61.00K
2020-12-31Reported-$30.68M(m)(m)$28.16M-108.95%$3.63M-$24.93M(m)$14.00M$28.79M$46.00K
2020-09-30Reported-$22.08M(m)(m)$32.43M-68.07%(m)(m)(m)(m)(m)(m)
2020-06-30Reported-$26.47M(m)(m)$21.21M-124.83%$2.85M*-$23.47M*(m)$10.44M$22.49M$21.00K
2020-03-31Reported-$30.53M(m)(m)$19.3M-158.20%$2.74M*-$58.67M*(m)$10.63M$27.19M$61.00K
2019-12-31Reported-$54.33M(m)(m)$17.16M-316.51%$2.06M-$34.91M(m)$10.30M$26.41M$37.00K
2019-09-30Reported-$30.08M(m)(m)$15.74M-191.14%(m)(m)(m)(m)(m)(m)
2019-06-30Reported-$26.53M(m)(m)$13.6M-195.10%$5.17M*-$22.08M*(m)$9.01M$21.32M$54.00K
2019-03-31Reported-$24.7M(m)(m)$13.56M-182.19%$3.77M*-$20.81M*(m)$8.91M$19.12M$84.00K
2018-12-31Reported-$21.43M(m)(m)$11.49M-186.43%$1.92M-$21.68M(m)$7.27M$15.26M$43.00K
2018-09-30Reported-$18.38M(m)(m)$8.41M-218.57%(m)(m)(m)(m)(m)(m)
2018-06-30Reported-$15.79M(m)(m)$6.54M-241.39%$629.00K*-$16.94M*(m)$5.27M$11.26M$71.00K
2018-03-31Reported-$15.2M(m)(m)$6.17M-246.56%$501.00K*-$16.51M*(m)$4.71M$9.98M$43.00K
2017-12-31Reported-$15.47M(m)(m)$4.31M-358.57%$1.51M-$16.02M(m)$4.30M$9.26M$52.00K

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-09-30Reported-$111.41M(m)(m)$376.57M-29.58%$28.00M-$47.63M(m)$80.28M$246.98M$719.00K
2024-09-30Reported-$189.4M(m)(m)$312.97M-60.52%$5.08M-$64.09M(m)$90.85M$218.40M$560.00K
2023-09-30Reported-$187.85M(m)(m)$245.11M-76.64%$27.78M-$142.47M(m)$106.89M$189.74M$1.15M
2022-09-30Reported-$218.26M(m)(m)$203.57M-107.22%$101.86M-$124.39M(m)$120.31M$212.95M-$10.41M
2021-09-30Reported-$142.98M(m)(m)$132.33M-108.04%$27.06M-$112.24M(m)$69.07M$135.90M-$1.93M
2020-09-30Reported-$133.4M(m)(m)$90.1M-148.06%$9.87M-$142.25M(m)$43.01M$103.27M$382.00K
2019-09-30Reported-$102.74M(m)(m)$54.39M-188.91%$14.76M-$87.94M(m)$35.68M$80.13M$292.00K
2018-09-30Reported-$64.83M(m)(m)$25.43M-254.97%$3.69M-$66.16M(m)$20.35M$43.45M$242.00K
2017-09-30Reported-$53.46M(m)(m)$10.77M-496.53%$6.59M-$51.30M(m)$19.17M$26.06M$280.00K

Similar stocks

Stock NameCountryMarket CapPE Ratio
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
EXELIXIS, INC. (EXEL)United States$14.358B16.15
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Immunovant, Inc. (IMVT)United States$7.028B-14.78